Scholar Rock Holding Corporation

Equities

SRRK

US80706P1030

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 19:18:02 28/05/2024 BST			5-day change	1st Jan Change
10.3 ^USD	-3.42%		-16.38%	-45.43%

05-23	Transcript : Scholar Rock Holding Corporation Presents at UBS Obesity Therapeutics Day, May-23-2024 09:00 AM
05-22	Scholar Rock Starts Phase 2 Trial of Apitegromab in Obesity	MT

Scholar Rock Holding Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023

May 09, 2023 at 12:46 pm

Scholar Rock Holding Corporation reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 39.38 million compared to USD 7.95 million a year ago.

Latest news about Scholar Rock Holding Corporation

Transcript : Scholar Rock Holding Corporation Presents at UBS Obesity Therapeutics Day, May-23-2024 09:00 AM	05-23
Scholar Rock Starts Phase 2 Trial of Apitegromab in Obesity	05-22	MT
Scholar Rock Holding Corporation Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity	05-22	CI
Scholar Rock Holding Corporation and Scholar Rock, Inc. Enter into the Fourth Amendment to the Loan and Security Agreement	05-22	CI
Transcript : Scholar Rock Holding Corporation - Analyst/Investor Day	05-22
Scholar Rock Shares Fall on Wider-Than-Expected Q1 Loss	05-07	MT
Scholar Rock Holding Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Scholar Rock Shares Rise After Raymond James Initiates Coverage	03-28	MT
Raymond James Initiates Scholar Rock With Strong Buy Rating, $30 Price Target	03-28	MT
Scholar Rock Holding Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	03-19	CI
Scholar Rock Holding Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	03-19	CI
North American Morning Briefing : Investors -2-	03-18	DJ
North American Morning Briefing : Stock Futures -2-	03-11	DJ
Scholar Rock Announces Management Appointments	02-15	CI
Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management	02-06	CI
Scholar Rock Says FDA Clears Application for Trial of Obesity Treatment Apitegromab	01-23	DJ
Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity	01-23	CI
Transcript : Scholar Rock Holding Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 01:30 PM	01-09
Scholar Rock Holding Corporation(NasdaqGS:SRRK) added to S&P Biotechnology Select Industry Index	12-18	CI
Scholar Rock Holding Insider Sold Shares Worth $448,444, According to a Recent SEC Filing	12-15	MT
Certain Common Warrants of Scholar Rock Holding Corporation are subject to a Lock-Up Agreement Ending on 11-DEC-2023.	12-10	CI
Certain Restricted Stock Units of Scholar Rock Holding Corporation are subject to a Lock-Up Agreement Ending on 11-DEC-2023.	12-10	CI
Certain Stock Options of Scholar Rock Holding Corporation are subject to a Lock-Up Agreement Ending on 11-DEC-2023.	12-10	CI
Certain Common Stock of Scholar Rock Holding Corporation are subject to a Lock-Up Agreement Ending on 11-DEC-2023.	12-10	CI
Certain Pre-funded Warrants of Scholar Rock Holding Corporation are subject to a Lock-Up Agreement Ending on 11-DEC-2023.	12-10	CI

Chart Scholar Rock Holding Corporation

Duration

Period

More charts

Company Profile

Scholar Rock Holding Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of medicines for the treatment of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia. The Company's product candidate includes apitegromab, an inhibitor of the activation of latent myostatin for the treatment of spinal muscular atrophy (SMA) and is in the treatment of other myostatin-related disorders. Its product candidate also includes SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 (TGF?1) for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies. The Company is advancing multiple antibody profiles toward product candidate selection, including antibodies that selectively inhibit the activation of latent TGF?1 in the context of fibrotic extracellular matrix and that avoid perturbing TGF?1 presented by cells of the immune system.

Sector

Biotechnology & Medical Research

Calendar

03/06/2024 - American Society of Clinical Oncology Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.67 USD

Average target price

26.25 USD

Spread / Average Target

+146.02%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SCHOLAR ROCK HOLDING CORPORATION	-45.43%	851M
VERTEX PHARMACEUTICALS INCORPORATED	+9.86%	118B
REGENERON PHARMACEUTICALS, INC.	+10.22%	106B
BIONTECH SE	-11.86%	23.4B
ARGENX SE	-1.69%	22.1B
GENMAB A/S	-10.23%	18.34B
WUXI APPTEC CO., LTD.	-41.92%	16.59B
BEIGENE, LTD.	-15.67%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+6.26%	14.03B
SAREPTA THERAPEUTICS, INC.	+14.78%	11.67B

Bio Therapeutic Drugs